---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-24-002081"
form_type: "8-K"
ticker: "HSCS"
cik: "0001468492"
company_name: "HeartSciences Inc."
filed_at: "2024-07-29T23:59:59+00:00"
generated_at: "2026-05-31T15:41:28.034074+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# HeartSciences reports FY2024 cash of $5.8M; cloud-platform beta and FDA timeline updates

## Summary
- Cash and equivalents $5.8M; shareholders' equity $7.3M as of April 30, 2024.
- Net proceeds of $10.3M from stock sales; $1.1M debt converted to equity.
- Issued common stock to Mount Sinai for algorithm licenses, recognizing $1.6M intangible asset.
- MyoVista Insights cloud-platform beta completed; FDA submission targeted for mid-2025.
- MyoVista wav ECG device FDA submission expected in Q1 2025 after final testing.

## SEC filing metadata
- accession: 0001013762-24-002081
- form_type: 8-K
- ticker: HSCS
- cik: 0001468492
- company_name: HeartSciences Inc.
- filed_at: 2024-07-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468492/000101376224002081/0001013762-24-002081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468492/000101376224002081/ea0210212-8k_heart.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-24-002081
- JSON: https://secwatch.observer/filing/0001013762-24-002081.json
- Plain text: https://secwatch.observer/filing/0001013762-24-002081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.